Related Experiment Video
Updated: Nov 15, 2025
Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses
Published on: April 4, 2019
The Future of Respiratory Syncytial Virus Disease Prevention and Treatment
Joseph B Domachowske1, Evan J Anderson2,3, Mitchell Goldstein4
1Department of Pediatrics, SUNY Upstate Medical University, Syracuse, NY, USA.
Insights
Respiratory syncytial virus (RSV) causes significant respiratory infections. While new treatments are developing, palivizumab remains crucial for preventing RSV in high-risk infants, despite some usage challenges.
Area of Science:
- Virology
- Immunology
- Pediatrics
Background:
- Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in vulnerable populations, including infants and immunocompromised adults.
- Current RSV treatment is mainly supportive, with limited options like aerosolized ribavirin facing efficacy, safety, and cost challenges.
- While new antiviral therapies are in early development, regulatory approval by the FDA is years away.
Purpose of the Study:
- To review the current landscape of Respiratory Syncytial Virus (RSV) treatment and prevention strategies.
- To evaluate the role of palivizumab (an RSV monoclonal antibody) in disease prevention.
- To discuss potential future directions for RSV prevention, including vaccines and novel monoclonal antibodies.
Main Methods:
- Literature review of existing studies on RSV treatments and immunoprophylaxis.
- Analysis of the efficacy, safety, and clinical challenges associated with palivizumab.
- Exploration of emerging RSV vaccine technologies and long-acting monoclonal antibodies.
Main Results:
- Palivizumab is the only licensed immunoprophylaxis (IP) for preventing RSV in specific high-risk pediatric groups, demonstrating established efficacy.
- Challenges to palivizumab use include cost, the need for monthly injections, and evolving AAP guidelines.
- New long-acting monoclonal antibodies show promise in early trials, and various vaccine strategies are under investigation.
Conclusions:
- Despite ongoing research into novel vaccines and treatments, palivizumab remains essential for reducing RSV disease burden in indicated high-risk populations.
- Continued use of palivizumab is recommended until more advanced preventative agents are licensed and widely available.
- Future RSV prevention may involve diverse strategies, including advanced vaccines and improved monoclonal antibody therapies.
Abstract:
Respiratory syncytial virus (RSV) is a major cause of respiratory tract infections in infants, young children, and older or immunocompromised adults. Although aerosolized ribavirin was licensed for RSV treatment on the basis of data demonstrating a reduced need for supplemental oxygen, ribavirin use is limited because of issues with efficacy, safety, and cost. Currently, the treatment of RSV is primarily supportive. New antiviral treatments for RSV are in the early stages of development, but it will be years until any of these may be licensed by the US Food and Drug Administration (FDA). Palivizumab, an RSV monoclonal antibody [immunoprophylaxis (IP)], has demonstrated effectiveness in disease prevention and is the only licensed IP for RSV disease in specific high-risk pediatric populations. Although its efficacy is well established, some challenges that may interfere with its clinical use include cost, need for monthly injections, and changing policy for use by the American Academy of Pediatrics (AAP). Preventing RSV disease would be possible through RSV vaccine development (e.g., live-attenuated, vector-based subunit, or particle-based). Alternatively, new long-acting monoclonal antibodies have demonstrated promising results in early clinical trials. Despite scientific advances, until new agents become available, palivizumab should continue to be used to reduce RSV disease burden in high-risk patients for whom it is indicated.
More Related Videos
09:14An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
Published on: January 26, 2019
09:01An In vitro Model to Study Immune Responses of Human Peripheral Blood Mononuclear Cells to Human Respiratory Syncytial Virus Infection
Published on: December 10, 2013
Related Concept Videos
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
01:29Microorganisms in Medicine and Therapeutics
01:24Cystic Fibrosis: Management
Sinus disease and chronic...
01:31Common Respiratory Disorders
Upper respiratory disorders impact the airways above the vocal cords, encompassing areas like the nose, sinuses, and throat. Various conditions fall under this category, including the common cold and allergic rhinitis. These disorders can stem from several causes,...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.